|
|
胃癌新辅助化疗的研究进展
|
Abstract:
胃癌是消化系统常见的恶性肿瘤，发病率和病死率均较高。以手术和化疗为主的综合治疗是胃癌的标准治疗方式，胃癌新辅助化疗作为胃癌综合治疗的一部分已得到越来越多的关注，其在胃癌治疗中的地位日趋重要。虽然新辅助化疗能够改善胃癌患者的治疗效果，但西方国家和东亚国家对于具体的用药方案尚未形成共同的理念。
Gastric cancer is a common malignant tumor of digestive system, with high incidence and mortality. The comprehensive treatment based on surgery and chemotherapy is the standard treatment for gastric cancer. Neoadjuvant chemotherapy for gastric cancer, as a part of comprehensive treatment for gastric cancer, has attracted more and more attention, and its position in the treatment of gastric cancer is becoming more and more important. Although neoadjuvant chemotherapy can improve the therapeutic effect of gastric cancer patients, western countries and East Asian countries have not formed a common concept for specific drug regimens.
| [1] | Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. and Jemal, A. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424. https://doi.org/10.3322/caac.21492 |
| [2] | 王少明, 郑荣寿, 张思维, 曾红梅, 陈茹, 孙可欣, 等. 2015年中国胃癌流行特征分析[J]. 中华流行病学杂志, 2019, 40(12): 1517-1521. |
| [3] | Sasako, M., Sakuramoto, S., Katai, H., Kinoshita, T., Furukawa, H., Yamaguchi, T., et al. (2011) Five-Year Outcomes of a Randomized Phase III Trial Comparing Adjuvant Chemotherapy with S-1 versus Surgery alone in Stage II or III Gastric Cancer. Journal of Clinical Oncology, 29, 4387-4393. https://doi.org/10.1200/JCO.2011.36.5908 |
| [4] | Petrillo, A., Pompella, L., Tirino, G., Pappalardo, A., Laterza, M.M., Caterino, M., et al. (2019) Perioperative Treatment Inresectable Gastric Cancer: Current Perspectives and Future Directions. Cancers, 11, Article No. 399.
https://doi.org/10.3390/cancers11030399 |
| [5] | Smith, D.D., Schwarz, R.R. and Schwarz, R.E. (2005) Impact of Total Lymph Nodecount on Staging and Survival After Gastrectomy for Gastric Cancer: Data from a Large US-Population Database. Journal of Clinical Oncology, 23, 7114-7124. https://doi.org/10.1200/JCO.2005.14.621 |
| [6] | 王玮, 孙哲, 邓靖宇, 王振宁, 周志伟, 梁寒, 等. 基于多中心大样本数据库的胃癌外科治疗相关数据的整合与分析[J]. 中华胃肠外科杂志, 2016, 19(2): 179-185. |
| [7] | Bang, Y.J., Kim, Y.W., Yang, H.K., Chung, H.C., Park, Y.-K., Lee, K.H., et al. (2012) Adjuvant Capecitabine and Oxaliplatin for Gastric Cancer after D2 Gastrectomy (CLASSIC): A Phase 3 Open-Label, Randomised Controlled trial. Lancet, 379, 315-321. https://doi.org/10.1016/S0140-6736(11)61873-4 |
| [8] | Das, M. (2017) Neoadjuvant Chemotherapy: Survival Benefit in Gastric Cancer. The Lancet Oncology, 18, e307.
https://doi.org/10.1016/S1470-2045(17)30321-2 |
| [9] | Hu, Y., Hu, D., Li, W, et al. (2019) Neoadjuvant Chemotherapy Brings More Survival Benefits Than Postoperative Chemotherapy for Resectable Gastric Cancer: A Meta-Analysis of Randomized Controlled Trials. Journal of BUON, 24, 201-214. |
| [10] | Heinemann, V. and Moosmann, N. (2007) Neoadjuvant and Adjuvant Therapies for Solid Tumours. MMW Fortschritte der Medizin, 149, 27-30. |
| [11] | Cunningham, D., Allum, W.H., Stenning, S.P., Thompson, J.N., Van de Velde, C.J.H., Nicolson, M., et al. (2006) Perioperative Chemotherapy versus Surgery alone for Resectable Gastroesophageal Cancer. New England Journal of Medicine, 355, 11-20. https://doi.org/10.1056/NEJMoa055531 |
| [12] | Ychou, M., Boige, V., Pignon, J., Conroy, T., Bouché, O., Lebreton, G., et al. (2011) Perioperative Chemotherapy Compared with Surgery alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial. Journal of Clinical Oncology, 29, 1715-1721. https://doi.org/10.1200/JCO.2010.33.0597 |
| [13] | Zhang, X.T., Liang, H., Li, Z.Y., Xue, Y.W., Wang, Y., Zhou, Z.W., et al. (2021) Perioperative or Postoperative Adjuvant Oxaliplatin with S-1 versus Adjuvant Oxaliplatin with Capecitabine in Patients with Locally Advanced Gastric or Gastro-Oesophageal Junction Adenocarcinoma Undergoing D2 Gastrectomy (RESOLVE): An Open-Label, Superiority and Non-Inferiority, Phase 3 Randomised Controlled Trial. Lancet Oncology, 22, 1081-1092.
https://doi.org/10.1016/S1470-2045(21)00297-7 |
| [14] | Endo, S., Imano, M., Furukawa, H., Yokokawa, M., Nishimura, Y., Shinkai, M., et al. (2019) Phase II Study of Preoperative Radiotherapy Combined with S-1 Plus Cisplatin in Clinically Resectable Type 4 or Large Type 3 Gastric Cancer: OGSG1205. Annals of Oncology, 30, v302. https://doi.org/10.1093/annonc/mdz247.110 |
| [15] | Al-Batran, S.E., Homann, N., Pauligk, C., Goetze, T.O., Meiler, J., Kasper, S., et al. (2019) Perioperative Chemotherapy with Fluorouracil Plus Leucovorin, Oxaliplatin, and Docetaxel versus Fluorouracil or Capecitabine Plus Cisplatin and Epirubicin for Locally Advanced, Resectable Gastric or Gastro-Oesophageal Junction Adenocarcinoma (FLOT4): A Randomised, Phase 2/3 Trial. Lancet Oncology, 393, 1948-1957. https://doi.org/10.1016/S0140-6736(18)32557-1 |
| [16] | Terazawa, T., Matsuyama, J., Goto, M., Kawabata, R., Endo, S., Imano, M., et al. (2020) A Phase II Study of Perioperative Capecitabine Plus Oxaliplatin Therapy for Clinical SS/SE N1-3 M0 Gastric Cancer (OGSG 1601). Oncologist, 25, 119-e208. https://doi.org/10.1634/theoncologist.2019-0601 |
| [17] | Wang, X.X., Li, S., Xie, T.Y., Lu, Y., Guo, X. and Lin, C. (2020) Early Results of the Randomized, Multicenter, Controlled Evaluation of S-1 and Oxaliplatin as Neoadjuvant Chemotherapy for Chinese Advanced Gastric Cancer Patients(RESONANCE Trial). Journal of Clinical Oncology, 38, S280. https://doi.org/10.1200/JCO.2020.38.4_suppl.280 |
| [18] | Yu, Y.Y., Fang, Y., Shen, Z.B., Wang, Y., Yan, M., Cao, H., et al. (2019) Oxaliplatin Plus Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Adenocarcinoma in Combination with D2 Gastrectomy: NEO-CLASSIC Study. Oncologist, 24, 1311-e989. https://doi.org/10.1634/theoncologist.2019-0416 |
| [19] | Al-Batran, S.E., Hofheinz, R.D., Pauligk, C., Kopp, H.-G., Haag, G.M., Luley, K.B., et al. (2016) Histopathological Regression after Neoadjuvant Docetaxel, Oxaliplatin, Fluorouracil, and Leucovorin versus Epirubicin, Cisplatin, and Fluorouracil or Capecitabine in Patients with Resectable Gastric or Gastro-Oesophageal Junction Adenocarcinoma (FLOT4-AIO): Results from the Phase 2 Part of a Multicentre, Open-Label, Randomised Phase 2/3 Trial. Lancet Oncology, 17, 1697-1708. https://doi.org/10.1016/S1470-2045(16)30531-9 |
